Please login (Members) to view content or
(Nonmembers) this article.

No votes yet

CNE Article

Cytokine Release Syndrome: Inpatient Care for Side Effects of CAR T-Cell Therapy

Laura T. Smith
Kimberly Venella
CJON 2017, 21(2), 29-34 DOI: 10.1188/17.CJON.S2.29-34

Background: Pediatric patients with relapsed and refractory acute lymphoblastic leukemia are more often being treated with chimeric antigen receptor (CAR) T-cell therapy. As with any new therapy, the management of this patient population has a unique set of challenges. The side effects of this therapy can range from mild to severe, with cytokine release syndrome being the most common reason for hospitalization.

Objectives: This article presents common side effects, treatments, and challenges of caring for hospitalized patients who have received CAR T-cell therapy.

Methods: A case study is used to illustrate a patient’s inpatient hospitalization course after receiving CAR T-cell therapy, including the management of treatment-related toxicities.

Findings: As treatments emerge, nurses will be challenged with learning the associated side effects and toxicities. CAR T-cell therapy can result in a unique trajectory of potential symptoms and the potential for complete resolution of disease.

Earn contact hours: ONS members can receive free CNE for reading this article and completing an evaluation online. To do so, click HERE or visit to access a current list of all available activities. This article's CNE is available for two years from the date of publication.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or